Vobarilizumab

Vobarilizumab
Monoclonal antibody
Type	Single-chain variable fragment
Source	Humanized
Target	IL6R
Clinical data
Other names	ALX0061
ATC code	none;
Identifiers
CAS Number	1628814-88-9;
ChemSpider	none;
UNII	9OD8ISS64U;
KEGG	D11005;
Chemical and physical data
Formula	C1118H1757N315O364S8
Molar mass	25691.68 g·mol−1

Vobarilizumab (INN; development code ALX0061) is a humanized bispecific nanobody (Llama-derived heavy-chain only (Vhh) antibody) designed for the treatment of inflammatory autoimmune diseases.^[1]^[2]^[3]

^ Statement On A Nonproprietary Name Adopted By The USAN Council - Vobarilizumab, American Medical Association.
^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
^ Hassan N, Choy E (September 2020). "Interleukin-6 inhibitors". In Scott DL, Galloway J, Cope A, Pratt A, Strand V (eds.). Oxford Textbook of Rheumatoid Arthritis. Oxford University Press. p. 394. doi:10.1093/med/9780198831433.003.0032. ISBN 978-0-19-256710-9.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Vobarilizumab, American Medical Association.

[2] World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).

[3] Hassan N, Choy E (September 2020). "Interleukin-6 inhibitors". In Scott DL, Galloway J, Cope A, Pratt A, Strand V (eds.). Oxford Textbook of Rheumatoid Arthritis. Oxford University Press. p. 394. doi:10.1093/med/9780198831433.003.0032. ISBN 978-0-19-256710-9.

[1]

[2]

[3]